Abstract
Purpose
Current clinical recommendations do not emphasise superiority of any of diuretics, but available reports are very encouraging and suggest beneficial effects of torasemide. This study aimed to compare the effect of torasemide and furosemide on long-term outcomes and New York Heart Association (NYHA) class change in patients with chronic heart failure (HF).
Methods
Of 2019 patients enrolled in Polish parts of the heart failure registries of the European Society of Cardiology (Pilot and Long-Term), 1440 patients treated with a loop diuretic were included in the analysis. The main analysis was performed on matched cohorts of HF patients treated with furosemide and torasemide using propensity score matching.
Results
Torasemide was associated with a similar primary endpoint (all-cause death; 9.8% vs. 14.1%; p = 0.13) occurrence and 23.8% risk reduction of the secondary endpoint (a composite of all-cause death or hospitalisation for worsening HF; 26.4% vs. 34.7%; p = 0.04). Treatment with both torasemide and furosemide was associated with the significantly most frequent occurrence of the primary (23.8%) and secondary (59.2%) endpoints. In the matched cohort after 12 months, NYHA class was higher in the furosemide group (p = 0.04), while furosemide use was associated with a higher risk (20.0% vs. 12.9%; p = 0.03) of worsening ≥ 1 NYHA class. Torasemide use impacted positively upon the primary endpoint occurrence, especially in younger patients (aged < 65 years) and with dilated cardiomyopathy.
Conclusions
Our findings contribute to the body of research on the optimal diuretic choice. Torasemide may have advantageous influence on NYHA class and long-term outcomes of HF patients, especially younger patients or those with dilated cardiomyopathy, but it needs further investigations in prospective randomised trials.
Similar content being viewed by others
References
Ponikowski P, Voors AA, Anker SD, Bueno H, Cleland JG, Coats AJ, et al. 2016 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure: the Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure of the European Society of Cardiology (ESC) developed with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur Heart J. 2016;37:2129–200.
Mueller TM, Vuckovic KM, Knox DA, Williams RE. Telemanagement of heart failure: a diuretic treatment algorithm for advanced practice nurses. Heart Lung. 2002;31:340–7.
Komajda M, Anker SD, Cowie MR, Filippatos GS, Mengelle B, Ponikowski P, et al. Physicians’ adherence to guideline-recommended medications in heart failure with reduced ejection fraction: data from the QUALIFY global survey. Eur J Heart Fail. 2016;18:514–22.
Maggioni AP, Anker SD, Dahlstrom U, Filippatos G, Ponikowski P, Zannad F, et al. Are hospitalized or ambulatory patients with heart failure treated in accordance with European Society of Cardiology guidelines? Evidence from 12,440 patients of the ESC Heart Failure Long-Term Registry. Eur J Heart Fail. 2013;15:1173–84.
Domanski M, Norman J, Pitt B, Haigney M, Hanlon S, Peyster E, et al. Diuretic use, progressive heart failure, and death in patients in the Studies Of Left Ventricular Dysfunction (SOLVD). J Am Coll Cardiol. 2003;42:705–8.
Cosin J, Diez J, investigators T. Torasemide in chronic heart failure: results of the TORIC study. Eur J Heart Fail. 2002;4:507–13.
Murray MD, Deer MM, Ferguson JA, Dexter PR, Bennett SJ, Perkins SM, et al. Open-label randomized trial of torsemide compared with furosemide therapy for patients with heart failure. Am J Med. 2001;111:513–20.
Fortuno A, Muniz P, Ravassa S, Rodriguez JA, Fortuno MA, Zalba G, et al. Torasemide inhibits angiotensin II-induced vasoconstriction and intracellular calcium increase in the aorta of spontaneously hypertensive rats. Hypertension. 1999;34:138–43.
Harada K, Izawa H, Nishizawa T, Hirashiki A, Murase Y, Kobayashi M, et al. Beneficial effects of torasemide on systolic wall stress and sympathetic nervous activity in asymptomatic or mildly symptomatic patients with heart failure: comparison with azosemide. J Cardiovasc Pharmacol. 2009;53:468–73.
Lopez B, Querejeta R, Gonzalez A, Sanchez E, Larman M, Diez J. Effects of loop diuretics on myocardial fibrosis and collagen type I turnover in chronic heart failure. J Am Coll Cardiol. 2004;43:2028–35.
Balsam P, Tyminska A, Kaplon-Cieslicka A, Ozieranski K, Peller M, Galas M, et al. Predictors of one-year outcome in patients hospitalised for heart failure: results from the Polish part of the Heart Failure Pilot Survey of the European Society of Cardiology. Kardiol Pol. 2016;74:9–17.
Kaplon-Cieslicka A, Tyminska A, Peller M, Balsam P, Ozieranski K, Galas M, et al. Diagnosis, clinical course, and 1-year outcome in patients hospitalized for heart failure with preserved ejection fraction (from the Polish cohort of the European Society of Cardiology Heart Failure Long-Term Registry). Am J Cardiol. 2016;118:535–42.
Eshaghian S, Horwich TB, Fonarow GC. Relation of loop diuretic dose to mortality in advanced heart failure. Am J Cardiol. 2006;97:1759–64.
D’Agostino RB Jr. Propensity score methods for bias reduction in the comparison of a treatment to a non-randomized control group. Stat Med. 1998;17:2265–81.
Austin PC, Jembere N, Chiu M. Propensity score matching and complex surveys. Stat Methods Med Res. 2018;27:1240–57.
Mentz RJ, Hasselblad V, DeVore AD, Metra M, Voors AA, Armstrong PW, et al. Torsemide versus furosemide in patients with acute heart failure (from the ASCEND-HF trial). Am J Cardiol. 2016;117:404–11.
Muller K, Gamba G, Jaquet F, Hess B. Torasemide vs. furosemide in primary care patients with chronic heart failure NYHA II to IV—efficacy and quality of life. Eur J Heart Fail. 2003;5:793–801.
Anand IS, Kalra GS, Harris P, Poole-Wilson PA, Panzali A, De Giuli F, et al. Diuretics as initial and sole treatment in chronic cardiac failure. Cardioscience. 1991;2:273–8.
Packer M. The neurohormonal hypothesis: a theory to explain the mechanism of disease progression in heart failure. J Am Coll Cardiol. 1992;20:248–54.
Swedberg K, Eneroth P, Kjekshus J, Wilhelmsen L. Hormones regulating cardiovascular function in patients with severe congestive heart failure and their relation to mortality. CONSENSUS Trial Study Group. Circulation. 1990;82:1730–6.
Brater DC. Benefits and risks of torasemide in congestive heart failure and essential hypertension. Drug Saf. 1996;14:104–20.
Han LN, Guo SL, Lin XM, Shi XM, Zang CB, Yang LM, et al. Torasemide reduces dilated cardiomyopathy, complication of arrhythmia, and progression to heart failure. Genet Mol Res. 2014;13:7262–74.
Dini FL, Ghio S, Klersy C, Rossi A, Simioniuc A, Scelsi L, et al. Effects on survival of loop diuretic dosing in ambulatory patients with chronic heart failure using a propensity score analysis. Int J Clin Pract. 2013;67:656–64.
Ozierański K, Kapłon-Cieślicka A, Balsam P, Tymińska A, Wancerz A, Peller M, et al. Do β-blockers improve one-year survival in heart failure patients with atrial fibrillation? Results from the ESC-HF Registry. Pol Arch Intern Med. 2018.
Yilmaz MB, Gayat E, Salem R, Lassus J, Nikolaou M, Laribi S, et al. Impact of diuretic dosing on mortality in acute heart failure using a propensity-matched analysis. Eur J Heart Fail. 2011;13:1244–52.
Vargo DL, Kramer WG, Black PK, Smith WB, Serpas T, Brater DC. Bioavailability, pharmacokinetics, and pharmacodynamics of torsemide and furosemide in patients with congestive heart failure. Clin Pharmacol Ther. 1995;57:601–9.
Ballester MR, Roig E, Gich I, Puntes M, Delgadillo J, Santos B, et al. Randomized, open-label, blinded-endpoint, crossover, single-dose study to compare the pharmacodynamics of torasemide-PR 10 mg, torasemide-IR 10 mg, and furosemide-IR 40 mg, in patients with chronic heart failure. Drug Des Devel Ther. 2015;9:4291–302.
Kido H, Ohtaki Y. Torasemide (LUPRAC): a review of its pharmacological and clinical profile. Nihon Yakurigaku Zasshi. 2001;118:97–105.
Mentz RJ, Stevens SR, DeVore AD, Lala A, Vader JM, Abouezzeddine OF, et al. Decongestion strategies and renin-angiotensin-aldosterone system activation in acute heart failure. JACC Heart Fail. 2015;3:97–107.
Balsam P, Ozierański K, Tymińska A, Główczyńska R, Peller M, Fojt A, et al. The impact of torasemide on haemodynamic and neurohormonal stress, and cardiac remodelling in heart failure—TORNADO: a study protocol for a randomized controlled trial. Trials. 2017;18(1):36.
Mamcarz A, Filipiak KJ, Drozdz J, Nessler J, Tykarski A, Niemczyk M, et al. Loop diuretics: old and new ones—which one to choose in clinical practice? Experts’ group consensus endorsed by the Polish Cardiac Society Working Group on Cardiovascular Pharmacotherapy and Working Group on Heart Failure. Kardiol Pol. 2015;73:225–32.
Buggey J, Mentz RJ, Pitt B, Eisenstein EL, Anstrom KJ, Velazquez EJ, et al. A reappraisal of loop diuretic choice in heart failure patients. Am Heart J. 2015;169:323–33.
Funding
The study is financed from the statutory funds of the European Society of Cardiology (ESC).
Author information
Authors and Affiliations
Contributions
KO conceived of the idea for the study and performed the statistical analysis. KO and PB designed the analysis, conducted the data interpretation and wrote the manuscript. KO, PB, AKC, AT, RK, MG, MP, AW and MM researched the data. KJF and GO reviewed the manuscript. MGCL and APM designed and coordinated the registries. JD coordinated the registry nationwide. All authors edited and approved the final version of the manuscript.
Corresponding author
Ethics declarations
Conflict of Interest
The authors declare that they have no conflict of interest.
Ethical Approval
This article does not contain any studies with animals performed by any of the authors. All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards.
Informed Consent
Informed consent was obtained from all individual participants included in the study.
Additional information
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
About this article
Cite this article
Ozierański, K., Balsam, P., Kapłon-Cieślicka, A. et al. Comparative Analysis of Long-Term Outcomes of Torasemide and Furosemide in Heart Failure Patients in Heart Failure Registries of the European Society of Cardiology. Cardiovasc Drugs Ther 33, 77–86 (2019). https://doi.org/10.1007/s10557-018-6843-5
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10557-018-6843-5